Negative news from Lipidor AB

Yesterday, Lipidor AB unexpectedly announced a negative result from the phase III trial with AKP02G2 for the treatment of psoriasis, and today the board decided to apply for bankruptcy.
The result is a major surprise and under the circumstances with no cash at hand, we agree with the board, that there is no realistic alternative.
For the patients and for LSIF together with more than 6.000 fellow shareholders, this is a regrettable and very unfortunate outcome.
For LSIF, it will not have any impact on our aim and ability to support our existing portfolio going forward, but we will carefully consider reducing planned new investments for the near future.